Immunome (IMNM) Other Non-Current Liabilities (2020 - 2023)

Immunome has reported Other Non-Current Liabilities for 4 years, with the latest figure at $1.3 million in Q4 2023.

• For the quarter ending Q4 2023, Other Non-Current Liabilities rose 2061.29% year-over-year to $1.3 million; the trailing twelve-month figure through Dec 2023 stood at $1.3 million (up 2061.29% YoY), and the FY2023 full-year result was $1.3 million, up 2061.29% from the prior year.
• Other Non-Current Liabilities for Q4 2023 stood at $1.3 million, up from $122000.0 in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $7.1 million in Q3 2020, with the low at $12000.0 in Q4 2021.
• Historically, Other Non-Current Liabilities has averaged $1.1 million across 4 years, with a median of $123000.0 in 2022.
• The largest YoY upside for Other Non-Current Liabilities was 2061.29% in 2023 against a maximum downside of 31.18% in 2023.
• Immunome's Other Non-Current Liabilities stood at $7.1 million in 2020, then slumped by 99.83% to $12000.0 in 2021, then surged by 416.67% to $62000.0 in 2022, then soared by 2061.29% to $1.3 million in 2023.
• The last three Other Non-Current Liabilities figures came in at $1.3 million (Q4 2023), $122000.0 (Q3 2023), and $62000.0 (Q4 2022), per Business Quant data.